The young and old are particularly vulnerable to infection from respiratory syncytial virus (RSV). It is the leading cause of lower respiratory disease for children younger than 4 years, and globally, nearly all children are infected by age two.1 On the other side of the age continuum, RSV is also common in adults older than 65 and their risk of serious infection increases with age.2
Timely results from cobas® Influenza A/B & RSV help guide clinical response for infection management and control. Performance of the cobas® Influenza A/B & RSV test was compared with an FDA-cleared, laboratorybased, multiplexed, real-time, reverse transcription PCR (RT-PCR) test across three targets.
The cobas® Influenza A/B & RSV Nucleic acid test for use on the cobas® Liat® System is a real-time polymerase chain reaction (PCR) test that detects and differentiates Influenza A, Influenza B and RSV in 20 minutes and is available now for use in laboratories, hospitals, physician officies and urgent care settings.
The cobas® Influenza A/B and RSV Nucleic acid test for use on the cobas® Liat® System is an automated multiplex real-time RT-PCR assay for the rapid in vitro qualitative detection and discrimination of Influenza A virus, Influenza B virus and respiratory syncytial virus (RSV) RNA in nasopharyngeal swab specimens from patients with signs and symptoms of respiratory infection in conjunction with clinical and epidemiological risk factors. The test is intended for use as an aid in the differential diagnosis of Influenza A, Influenza B, and RSV in humans and is not intended to detect Influenza C.
The cobas® Liat® System is commercially available in select markets. This product is not registered as an in vitro diagnostic (IVD) in all countries; additional information may be available from your Roche sales representative.
CE-IVD, FDA 510(k) cleared, CLIA waived
Access package inserts through your country’s Roche Diagnostics Website.